171 related articles for article (PubMed ID: 36170157)
1. RNA sequencing and bioinformatics analysis revealed PACSIN3 as a potential novel biomarker for platinum resistance in epithelial ovarian cancer.
Han GH; Shim JE; Yun H; Kim J; Kim JH; Cho H
J Gene Med; 2022 Nov; 24(11):e3452. PubMed ID: 36170157
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling of epithelial ovarian cancer reveals key genes and pathways associated with chemotherapy resistance.
Zhang M; Luo SC
Genet Mol Res; 2016 Jan; 15(1):. PubMed ID: 26909918
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
4. High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer.
Han GH; Yun H; Chung JY; Kim JH; Cho H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36999629
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
6. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.
Koti M; Gooding RJ; Nuin P; Haslehurst A; Crane C; Weberpals J; Childs T; Bryson P; Dharsee M; Evans K; Feilotter HE; Park PC; Squire JA
BMC Cancer; 2013 Nov; 13():549. PubMed ID: 24237932
[TBL] [Abstract][Full Text] [Related]
7. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
[TBL] [Abstract][Full Text] [Related]
8. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
Pénzváltó Z; Lánczky A; Lénárt J; Meggyesházi N; Krenács T; Szoboszlai N; Denkert C; Pete I; Győrffy B
BMC Cancer; 2014 Nov; 14():837. PubMed ID: 25408231
[TBL] [Abstract][Full Text] [Related]
9. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
10. CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer.
Nie S; Wan Y; Wang H; Liu J; Yang J; Sun R; Meng H; Ma X; Jiang Y; Cheng W
J Ovarian Res; 2021 Sep; 14(1):115. PubMed ID: 34474677
[TBL] [Abstract][Full Text] [Related]
11. [Bioinformatics analysis of drug-resistant ceRNA in epithelial ovarian cancer].
Pan ZM; Tan FC; Chen CX; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2021 Feb; 56(2):121-130. PubMed ID: 33631884
[No Abstract] [Full Text] [Related]
12. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
14. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
15. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
16. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
17. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
[TBL] [Abstract][Full Text] [Related]
18. High co-expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer.
Wu X; Shen S; Qin J; Fei W; Fan F; Gu J; Shen T; Zhang T; Cheng X
BJOG; 2022 Nov; 129 Suppl 2(Suppl 2):40-49. PubMed ID: 36485069
[TBL] [Abstract][Full Text] [Related]
19. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract][Full Text] [Related]
20. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
Ceccaldi R; O'Connor KW; Mouw KW; Li AY; Matulonis UA; D'Andrea AD; Konstantinopoulos PA
Cancer Res; 2015 Feb; 75(4):628-34. PubMed ID: 25634215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
